Fifty percent growth inhibition occurred at similar dose levels for MN1-driven AML and Kmt2a-Mllt3 driven murine AML, although it should be noted that in the Kmt2a-Mllt3 model, responses occurred earlier, and higher doses resulted in considerably more profound inhibition (Fig. 5B and Supplementary Fig. S4B, C). The gene discussed is MLLT3; the disease is acute myeloid leukemia.